Therapeutic potential of metabotropic glutamate receptor 7 modulation in correcting cognitive deficits of schizophrenia
is proposed to be a viable therapeutic target to treat cognitive deficits driven by glutamatergic dysfunction in disorders including schizophrenia.
Authors
- Kimberly M. Holter (ORCID: https://orcid.org/0000-0002-9315-6332)
- Niki M. Harris
- Colleen M. Niswender
Institutions
- Allen Institute for Brain Science (US)
- Vanderbilt University (US)
- Center for Discovery (US)
- Vanderbilt Health (US)
- Vanderbilt University Medical Center (US)
Publication Details
- Journal
- Schizophrenia Research
- Published
- 2026-06-17
- DOI
- https://doi.org/10.1016/j.schres.2026.06.012
- Primary Topic
- Neuroscience and Neuropharmacology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institute of Mental Health
- National Institute of Neurological Disorders and Stroke